INTRODUCTION
Chronic, nonhealing, full-thickness wounds of the lower extremity frequently occur secondary to diabetes, infection, ischemia, and trauma. 1, 2 Bioengineered skin grafts are an alternative treatment for such wounds, which often are unresponsive to traditional wound management modalities. 1 Several studies have demonstrated successful outcomes using a human acellular dermal regenerative tissue matrix to heal chronic, full-thickness wounds of the lower extremity. 1 -3 Although these studies demonstrate the safety of this matrix, limitations include small patient populations with relatively strict inclusion criteria. 1 -3 This study is the first multicenter study involving the use of a human acellular dermal regenerative tissue matrix for the treatment of a wide array of lower extremity wounds in a diabetic patient population.
MATERIALS AND METHODS

Patient Selection
Between April 2004 and June 2006, 75 diabetic patients (100 wounds) were treated with a human acellular dermal regenerative tissue matrix (GRAFTJACKET Matrix or GRAFTJACKET Matrix Ulcer Repair; Wright Medical Technology Inc, Arlington, Tennessee). Four podiatric surgeons at 4 institutions performed all surgeries. Patients who were at least 18 years old and presented to one of the podiatric surgeons with chronic, nonhealing, full-thickness wounds for which conservative treatment failed were included in this study. Partial-thickness wounds were excluded from this study. Wounds were classified according to initial presentation using the University of Texas (UT) Wound Classification System (Table 1) . 4, 5 Patient records were also reviewed to ascertain time to matrix incorporation, 100% granulation, and complete healing. The primary wound outcome end point was time to complete healing or matrix failure. Secondary wound outcome end
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Statistical Analysis
An independent statistician performed the statistical analysis using version 2.0 of the SigmaStat software (SPSS Inc, Chicago, Illinois). Descriptive statistics, including mean, median, SD, frequency, and percentage, were used to describe numerical data. Demographic variables, patient comorbidity variables, and time to matrix incorporation, 100% granulation, and complete healing were compared between the UT grades. Pearson's chi-square analysis was used to compare categorical information. For continuous variables that were normally distributed, 1-way analysis of variance was used to determine statistical significance. Kruskal-Wallis 1-way analysis of variance on ranks was used to compare non -normally distributed, continuous variables. Statistical differences were considered significant with P = .05, with a power of at least 0.8. Ninety-five percent confidence intervals were used throughout the statistical analysis.
Surgical Technique
Before matrix application, both infection and venous insufficiency were addressed using standard clinical protocols for diagnosis and management. Before surgery, necrotic tissue was removed by sharp debridement or by using an enzymaticdebriding agent, an antimicrobial dressing containing silver or polyhexamethylene biguanide, or an antimicrobial dressing containing cadexomer iodine.
Both the GRAFTJACKET Matrix and GRAFTJACKET Matrix Ulcer Repair are immunologically inert, acellular regenerative tissue matrices derived from human cadaver tissue. These were used in all cases. The matrices (4 Â 4-, 4 Â 8-, 5 Â 5-, and 5 Â 10-cm sheets) were applied in both surgical and clinical settings. Matrix size was determined by the measurements obtained at the last preoperative evaluation. If needed, multiple matrices were combined to completely cover the surface area of large wounds. Patient positioning was dependent on wound location. After administering appropriate local and/or general anesthetic, the lower extremity was prepared and draped in standard sterile fashion.
Matrices were rehydrated for a minimum of 5 minutes. In the majority of cases, rehydration was achieved using a sterile saline bath. For the remaining patients, 10 cc of the patient's blood with 1000 U of heparin was mixed with either sterile saline or an antibiotic solution of bacitracin and polymyxin B. Standard full-thickness wound debridement was performed to remove as much necrotic tissue as possible and to create a fresh wound base. Wound edges were resected by 2 to 4 mm to create fresh granular edges for matrix fixation. A pulse vacuum with a minimum 3000-mL solution of saline and antibiotic or a topical hemostatic agent was applied to the wound. If used, the topical hemostatic agent was removed before matrix application. Fifteen minutes of sustained pressure was applied to control bleeding. If deemed necessary, the wound was irrigated with an antibiotic solution of bacitracin and polymyxin B using a glass or plastic asepto syringe with rubber bulb. 
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Before application, the matrix was removed from the saline solution, and the paper backing was removed. The reticular layer, or ''shiny side,'' of the matrix was placed against the wound bed, which orients the reticular surface to the vascular supply of adjacent tissue and the basement membrane, or ''dull side,'' superficially. The matrix was applied using skin staples or sutures (3.0 Prolene polypropylene or Ethilon nylon suture; Ethicon Inc, Somerville, New Jersey) in a simple or horizontal mattress suturing technique (Figure 2 ). Any excess matrix was trimmed using scissors during the matrix application. For large wound areas that required more than 1 matrix, sutures or staples were used to attach the additional matrices.
After matrix application, 1 of 2 wound dressing application methods was employed. Fluffed 4 Â 4-cm gauze pads soaked in sterile mineral oil (30-mL Mineral Oil Lubricant Laxative Dose Packs; Pharmaceutical Associates Inc, Greenville, South Carolina) were placed directly onto the matrix area, followed by Xeroform gauze (Integrity Medical Devices Inc, Elwood, New Jersey), abdominal dressings, Kerlix A.M.D. Antimicrobial Large Roll dressings (The Kendall Co, Mansfield, Massachusetts), and Ace-style wraps. Alternatively, Xeroform gauze soaked in sterile mineral oil was applied directly over the matrix, followed by 4 Â 4-cm gauze pads soaked in sterile mineral oil, Kerlix A.M.D. Antimicrobial Large Roll dressings, and Ace-style wraps.
Patients were discharged upon confirmation of stable vital signs and intact vascular status of the operative extremity, with non -weight-bearing ambulation, appropriate to patient ability. If noncompliance was suspected, the use of a wheelchair was implemented.
Postoperative Wound Management
Postoperative wound management was divided into 3 stages: incorporation of the matrix, release of the basement membrane, and epithelialization across the wound. Matrix incorporation into the wound bed typically begins during this immediate postoperative period (Figure 3) . At the first postoperative wound evaluation, mineral oil (30-mL Mineral Oil Lubricant Laxative Dose Packs; Pharmaceutical Associates Inc) was applied directly to the matrix area, followed by application of a compressive moisture-retentive dressing. For cases performed on an inpatient basis, the initial postoperative dressings were removed within the first 48 hours for monitoring purposes, especially if associated with a previous history of infection. Otherwise, these mineral oil compressive dressing changes were initiated during the first office visit 3 to 8 days after matrix application and were continued every 5 to 7 days until the basement membrane began to dry. If the dressing selections were unable to control excessive drainage at the first postoperative visit, a wound vacuum was applied until the matrix was incorporated and exudates ceased, or until the basement membrane was released to reveal a healing wound, at which time the standard wound management protocol was resumed. During the early stages of matrix incorporation, aggressive drying agents were avoided, as such products may 
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prevent cellular repopulation and revascularization and possibly lead to sloughing of the matrix.
As the basement membrane began to dry, a wound veil, an antimicrobial dressing, and a foam dressing were applied sequentially every 3 days until the basement membrane was released (Figure 4 ). Alternatively, a contact layer dressing and an antimicrobial dressing containing cadexomer iodine were used for up to 7 days, until the basement membrane was released. If excessive drainage was present during this stage, an antimicrobial dressing with moisture control was used. After release of the basement membrane, collagenase ointment was applied to wounds with granular wound beds that exhibited no substantial decrease in wound measurements to promote epithelialization. Other agents were also applied as necessary to promote epithelialization across the matrix. More aggressive measures, such as reapplication of another matrix, were used for wounds that were slow to heal. Wound healing was considered complete after release of the basement membrane with full epithelialization across the wound ( Figure 5 ).
RESULTS
The study population was composed of 35 women (46.7%) and 40 men (53.3%). The mean patient age was 62.7 years, with patients ranging in age from 40 to 92.9 years. Social history incidences included alcohol (17.0%), tobacco (34.0%), and combined (10.0%) usage. Comorbidities are presented in Figure 6 . One-third of the study population had uncontrolled diabetes. Eighty-six wounds (86.0%) were located on the foot, 8 (8.0%) were positioned on the ankle, and 6 (6.0%) involved the lower extremity. The mean wound age was 20.4 weeks (range, 1.3 -191.4 weeks).
As summarized in Table 2 , nearly one-half of the wounds were classified as UT grade 3, with wound depths penetrating to the bone or into the joint. One-third of all wounds were infected and ischemic. Time to matrix incorporation, 100% Table 3 . No matrix-related complications occurred.
Ten wounds, presenting in 8 patients, did not heal after initial matrix application, as summarized in Table 4 . Therefore, the matrix successfully healed 90 wounds (90.0%) in 67 patients (89.3%). A matrix was reapplied to 1 wound that failed because of patient noncompliance, which subsequently healed 7 weeks after reapplication. Because 91 of the original 100 wounds healed, the overall healing rate for this study population is 91.0%.
A subsequent comparison of the UT grades was conducted to differentiate any significant differences between the UT classification and time to matrix incorporation, 100% granulation, and complete healing (Table 3) . Before analyzing the wound outcome end points, demographic and patient comorbidity variables of interest were compared between UT grades. Because no statistically significant differences were observed, it then was appropriate to compare the time with matrix incorporation, 100% granulation, and complete healing of the various UT grades, as no confounding demographic or comorbidity differences were present between the UT grades that may adversely influence the outcomes. No statistically significant differences between the UT grades and time to matrix incorporation, 100% granulation, and complete healing were observed.
DISCUSSION
The literature reporting the use of this particular acellular regenerative tissue matrix for the treatment of diabetic lower extremity wounds comprises small patient populations and involves wounds that did not penetrate to tendon, capsule, or bone and were not infected or ischemic. 1 -3 The current study represents the first multicenter study that used this matrix as a treatment in a wider range of diabetic lower extremity wounds, including more complex wounds. A limitation of this retrospective study is that it includes chronic wounds with duration of at least 1 week in patients with a previous history of delayed healing compared with more common definitions of chronicity characterized by no improvement in at least 2 weeks. 6, 7 In patients with multiple wounds, treatment of the more severe wound dictated the timing of matrix application. In such cases, matrices also were applied to any other wound that failed conservative treatment. At the time of presentation, before matrix application, approximately one-half of the wounds were classified as UT grade 3. Of these wounds, 72.3% were both infected and ischemic. Overall, one-third of all wounds in this study were infected and ischemic, further complicating treatment. In addition to the complexity of the wounds, the majority of patients had concomitant health issues, as evidenced by the high incidences of comorbidities, including diabetes, cardiac disease, neuropathy, and obesity. Given the advanced state of many wounds and the poor health of this patient population, the mean time to complete healing of 13.8 weeks and the overall healing rate of 91.0% are quite remarkable.
Because the previously reported studies using the same human acellular dermal regenerative tissue matrix do not involve such complex wounds, it would not be appropriate to directly compare results between those studies and the overall results of the current study; however, similar trends can be observed. 2, 3 Using the same inclusion criteria as Martin et al, 2 that is, UT grade 2A neuropathic diabetic foot wounds healing by 20 weeks, the mean time to complete healing for the 9 UT 2A neuropathic diabetic foot wounds in the current study is 9.8 weeks. The mean time to complete healing of 8.9 weeks reported by Martin et al 2 is slightly less than this result, but may not be statistically significant. Unfortunately, because demographics and comorbidities cannot be compared because of variations in study design, potential differences between the study populations that may impact healing cannot be determined.
2
By extracting the results of noninfected and/or nonischemic UT grades 1 to 3 wounds healing within 12 weeks, the current study may be compared with that of Yeager and Oliverio. 3 The current study's mean healing time of 9.6 weeks for 22 wounds healing in less than 12 weeks is greater than the mean 6.9-week healing time reported among the 11 Wagner grade 1 or 2 full-thickness ulcers in the Yeager and Oliverio study, but may not be statistically significant. 3 Again, demographics and comorbidities cannot be compared between the studies, so the slightly higher mean healing time in this study may be due to the inclusion of patients with more complicated health histories. 3 When comparing the time to matrix incorporation, 100% granulation, and complete healing within the UT grades in the current study, no statistically significant differences were observed. The lack of significant differences between matrix incorporation, 100% granulation, and wound healing rates of the various UT grades may be attributed to the surgical technique, as well as to the graft itself. The relatively high rates of healing and lack of statistical significance between UT grades provide additional support to the safety of this human acellular dermal regenerative tissue matrix as a treatment option not only for chronic, full-thickness diabetic lower extremity wounds, but also for more complex wounds, including those penetrating to the bone or joint and those further complicated by infection and/or ischemia. Further controlled studies are recommended to determine the efficacy of this matrix as an alternative treatment option for such complex wounds, which are often considered unsalvageable and result in amputation. 
CONCLUSION
This study is the first multicenter study involving the use of a human acellular dermal regenerative tissue matrix and also is the largest series in a diabetic patient population reported to date demonstrating wound healing outcomes for the treatment of a wide range of chronic, nonhealing, full-thickness wounds in individuals with diabetes. These results support previous studies documenting the matrix's success in chronic, fullthickness wounds of the lower extremity. Furthermore, the absence of matrix-related complications, in addition to the relatively high rate of wound healing in this complex patient population, indicates that the matrix is a safe treatment option for more complicated, diabetic lower extremity wounds. In conclusion, this study substantiates the safety of this matrix, as there were no statistically significant differences between UT grades and time to matrix incorporation, 100% granulation, and complete healing, suggesting that it may be used safely in the full spectrum of chronic, diabetic lower extremity wounds.
Prospective, randomized, controlled studies are warranted to determine the efficacy of this matrix relative to the accepted standardized protocols of management of these wounds.
